CSIMarket.com ’
KalVista Pharmaceuticals, Inc. has recently provided significant updates on its investigational drug, EKTERLY (sebetralstat), a novel oral on-demand treatment for hereditary angioedema (HAE). The recent presentations at the 20th German Allergy Congress and the European Academy of Allergy and Clinical Immunology (EAACI) Congress in 2025 highlighted the potential of sebetralstat to transform the management of HAE, particularly in patients requiring on-demand therapies during acute attacks.
Hereditary angioedema is a rare genetic disorder characterized by recurrent episodes of severe swelling, which can be life-threatening and significantly impact quality of life. Current treatment options for HAE attacks include injectable therapies, which can be inconvenient and painful for patients. Sebetralstat, marketed as EKTERLY, is distinguished as the first and only oral medication designed specifically for the rapid treatment of these acute episodes.
At the recent German Allergy Congress, data from KalVista’s KONFIDENT and KONFIDENT-S studies were presented, demonstrating sebetralstat’s efficacy in rapidly halting the progression of HAE attacks. The clinical trial results indicated that patients experienced significant relief from symptoms with the use of EKTERLY, making it a viable alternative to existing injectable therapies. These findings mark a noteworthy step forward in addressing the unmet needs of HAE patients.
Further illuminating the significance of sebetralstat, KalVista presented additional findings at the EAACI Congress in Glasgow, which underscore the importance of effective on-demand treatments, particularly for patients already on long-term prophylactic therapies such as berotralstat, lanadelumab, or C1 inhibitors. The data suggests that EKTERLY can effectively manage breakthrough attacks during long-term prophylaxis, a critical aspect for optimizing patient care in HAE management.
While the data surrounding sebetralstat is promising, it is important to note that KalVista announced a delay from the U.S. Food and Drug Administration (FDA) regarding the review of its New Drug Application (NDA) due to FDA resource constraints. This notification, which postponed the previously set PDUFA goal date of June 17, 2025, has implications for the prospective accessibility of EKTERLY in the U.S. market.
In conclusion, the recent presentations of EKTERLY (sebetralstat) data at major medical conferences have illuminated its potential as a groundbreaking oral on-demand treatment option for HAE. As the clinical landscape for HAE evolves, sebetralstat may offer a significant advancement in patient care and quality of life for those suffering from this debilitating condition. The ongoing developments with the FDA will be closely monitored, as they will determine the future availability of this promising therapy.
Comments